

IPSEN IN BRIEF

2023

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.



STEVE
Living with kidney cancer
Crewe, UK

OUR STRATEGY

Focus. Together.
For patients & society.



Maximize our brands

Drive efficiencies

Strengthen pipeline

Focus on culture

GENERATION IPSEN 2022 ACHIEVEMENTS



Environment

- **Emissions** - GHG emission-reduction trajectory: officially certified by the Science Based Targets initiative¹
- **Renewables** - 90% renewable electricity for all global operations
- **Fleet** - Launched *Fleet for Future* programs

Patients

- **Access** - Partnership with *Access Accelerated*: continued to support communities that lack sufficient access to healthcare
- **Ukraine** - €1.5m donation to the Red Cross and Tulipe, plus medicine donations

People

- **Diversity** - Women: 48% of the Global Leadership Team
- **Employer of choice** - in 23 countries
- **Community** - 44% of colleagues participated in Ipsen's *Community Day*

Governance

- **Certification** - ISO 37001 certification for anti-corruption management systems
- **Compliance** - Continued rigorous compliance with highest ethics and compliance standards

IPSEN KEY FIGURES

€3.0bn

TOTAL SALES (2022)

~5,000

COLLEAGUES

100+

COUNTRIES WHERE
IPSEN MEDICINES ARE
MARKETED

The Company's research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs:

Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

¹ A collaboration between the CDP, the United Nations Global Compact, the World Resources Institute and the World Wide Fund for Nature. GHG: greenhouse gas.

THERAPEUTIC AREAS

ONCOLOGY

More than **35 years of research in Oncology** focusing on cancers with high unmet needs

RARE DISEASE

Teams of **global experts and researchers** developing life-changing treatments for **Rare Diseases**

NEUROSCIENCE


More than **25 years of Neuroscience expertise and innovation**



PALOVAROTENE



2022 TOTAL SALES AND GROWTH*



GEOGRAPHIC BREAKDOWN

Total sales by region: 2022

34%


NORTH AMERICA

41%

EUROPE

25%

REST OF THE WORLD



● Countries where Ipsen operates | ● Pharmaceutical development centers | ● R&D hubs



Craig Marks, Vice President,
Investor Relations
+44 (0) 7584 349 193

investor.relations@ipsen.com
ipsen.com/investors



* All growth rates are at constant exchange rates. Cumulative firepower by 2024 as at the end of 2022.